Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16572114 | 0.81 | LMNA (0.47) | HTTLMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL705283 | 0.79 | HTT (0.49) | HTTLMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL15802494 | 0.77 | HTT (0.46) | HTTLMNASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL708461 | 0.77 | L3MBTL1 (0.44) | HTTLMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL15807587 | 0.75 | HTT (0.46) | HTTLMNASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL15839479 | 0.74 | CTSS (0.46) | MAPTCTSLCTSBCTSS | |
| SCHEMBL15804484 | 0.74 | CTSS (0.46) | MAPTCTSLCTSBCTSS | |
| SCHEMBL19606644 | 0.73 | CTSS (0.45) | MAPTCTSLCTSBCTSS | |
| SCHEMBL15792219 | 0.73 | CTSS (0.45) | MAPTCTSLCTSBCTSS | |
| SCHEMBL15792222 | 0.73 | CTSS (0.45) | MAPTCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257296-B1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575176-B2 | Heteroaromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120116083-A1 | HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8124607-B2 | Poly aromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124607-B2 | Poly aromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2257296-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009139948-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090214444-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090214444-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116083-A1 | HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, KCNH1 | HTT 554/4885LMNA 1285/4885SMN1; SMN2 3343/4885 |
| US-20090214444-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCNN1B | HTT 723/4885LMNA 956/4885SMN1; SMN2 2733/4885 |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCNN1B | HTT 723/4885LMNA 956/4885SMN1; SMN2 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.